KCNQ1 and long QT syndrome 1: Conversely, Dotzler et al. performed isogenic CRISPR/Cas9 correction of KCNQ1 in type 1 LQTS (LQT1) hiPSC-CMs, which demonstrated normalized levels of action potential duration and served as a positive control for testing KCNQ1-SupRep (suppression-and-replacement) gene therapy in LQT1 hiPSC-CMs [85].